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a Durable Therapeutic Strategy?*
John G. Webb, MD, Danny Dvir, MDT ranscatheter aortic valve replacement (TAVR)has rapidly become standard therapy formany patients for whom open surgery is
considered “high risk.” However, recent favorable
experience in lower surgical risk patients suggests
that TAVR may assume a much broader role. For
this to be true, a “TAVR ﬁrst” strategy would
need to satisfy the needs of younger patients with
lesser morbidity in whom durability assumes greater
importance.
Bioprosthetic valves degenerate with time. Wear
and tear, calciﬁcation, pannus formation, endocar-
ditis, and thrombosis are the most common mech-
anisms of failure. Durability is determined by
numerous physical factors (e.g., tissue characteris-
tics, anticalciﬁcation treatments, leaﬂet and valve
design, and transvalvular gradients) as well as clinical
factors (e.g., patient age and various metabolic ab-
normalities). An optimal surgical bioprosthesis in an
optimal patient may last in excess of 20 years. Un-
fortunately, many surgical bioprostheses fail much
earlier (Figure 1). The potential for early failure was
evident in the recent Global Valve-in-Valve registry in
which the median age of failed surgical bioprostheses
treated with transcatheter heart valve (THV) implan-
tation was only 9 years (1).
The durability of THV frames has been of some
concern, particularly given previous experience with
fractures of some large-vessel stents and valved pul-
monary conduits. Fortunately, midterm durability of
more durable SAPIEN (Edwards Lifescience, Irvine,
California) and CoreValve (Medtronic, Minneapolis,*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
From St. Paul’s Hospital, Vancouver, British Columbia, Canada. Drs.
Webb and Dvir are consultants for Edwards Lifesciences.Minnesota) aortic frames has been well documented
in vitro and in vivo (2–4).
It is reasonable to anticipate that THV leaﬂets
might be at greater risk of early failure than surgical
valve leaﬂets. Predisposing factors include leaﬂet
trauma from compression within the delivery cath-
eter or balloon dilation, suboptimal leaﬂet coaptation
or leaﬂet-frame contact due to asymmetrical or
incomplete frame expansion, and suboptimal im-
plantation (5). The pursuit of lower proﬁle delivery
catheters has led to the use of thinner leaﬂet tissue,
with the potential for reduced durability. Departure
from established valve design principles and pro-
cesses opens the potential for new modes of failure.
Just as with surgical valves, the durability of all
transcatheter valves may not be equal. Will next-
generation THVs be as durable as those we have
begun to trust, or will there be disappointments?
Because of these concerns, the requirements for
approving THVs have been more rigorous than those
applied to surgical valves. In vitro durability is
routinely evaluated in accelerated wear testers for the
equivalent of 5 years under varying conditions (e.g.,
transvalvular pressure gradients, noncircular expan-
sion), and generally for much longer.
What do we know about real-world aortic THV
durability? There have been scattered reports of valve
failure due to leaﬂet degeneration (5–7). The pre-
dominant mechanism of failure has been progressive
leaﬂet calciﬁcation resulting in progressive reste-
nosis, whereas sudden and catastrophic regurgitation
due to leaﬂet tears has been rare (5–7).SEE PAGE 1084In this issue of JACC: Cardiovascular Interventions,
Barbanti et al. (8) add greatly to our knowledge
by reporting sustained clinical outcomes 5 years
after self-expandable CoreValve implantation. Valve
performance was excellent, with signs of mild to
FIGURE 1 Early Failure of a 1-Year-Old Surgical Valve
(A) Severe regurgitation due to a leaﬂet tear. (B) Trifecta surgical valve (St. Jude Medical, St. Paul, Minnesota). (C) SAPIEN XT (Edwards
Lifesciences, Irvine, California) transcatheter valve-in-valve implantation. Aortography shows no regurgitation.
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1093moderate prosthetic failure in only 2.8% and severe
failure in only 1.4%. Our group previously reported
similar sustained clinical and echocardiographic out-
comes beyond 5 years for balloon-expandable SAPIEN
and SAPIEN XT valves (9). Valve performance was
excellent, with moderate late prosthetic stenosis seen
in 3.4%, with no severe failure. Perhaps the most
rigorous evaluation is from the 5-year follow-up of the
PARTNER (Placement of AoRtic TraNscathetER Valve)
trial. Structural failure of transcatheter valves was not
observed. SAPIEN THVs had valve areas and gradients
identical to those of surgical bioprostheses (10,11).
As a consequence of the population under
study, follow-up beyond 5 years remains anecdotal
(Figure 2). It is clear from multiple sources that the
paucity of late survivors after TAVR is theFIGURE 2 Midterm Durability of a Transcatheter Heart Valve
(A) A bovine pericardial SAPIEN valve (Edwards Lifesciences, Irvine, Cali
mean gradient was 11 mm Hg with no aortic regurgitation. (C) The patie
revealed a durable valve with only minimal calciﬁcation.consequence of the advanced age and comorbidities
of the high-risk surgical population being treated, not
valve failure (10–12).
What will happen when TAVR is applied to lower
risk patients who may live long enough for their
transcatheter valves to fail? Surgery may be an option
for some. Removal of a purely annular valve (e.g.,
SAPIEN) can be relatively simple, although removal of
a THV that extends into the ascending aorta (e.g.,
CoreValve) may require a more extensive procedure
(5). However, favorable experience with THV im-
plantation in failed surgical and transcatheter bio-
prostheses has demonstrated that TAVR may be more
easily repeated than open surgery (13,14).
The durability of the currently available THVs
appears adequate for the great majority of elderlyfornia) was implanted in 2006. (B) Seven years later, the transaortic
nt died in 2013 of unrelated causes. Postmortem examination
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1094patients with contraindications to surgery currently
undergoing TAVR. Application in patients with longer
anticipated survival will require a strategy incor-
porating THVs with demonstrable durability and
repeatability.REPRINT REQUEST AND CORRESPONDENCE: Dr.
John Webb, St. Paul’s Hospital, 1081 Burrard Street,
Vancouver, British Columbia V6Z 1Y6., Canada.
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